Quanterix Statement on COVID-19 Preparedness, Resiliency Efforts and Business Continuity
As COVID-19 continues to affect a growing number of people in the
- Overcome interruptions in their laboratories
- Sustain clinical trials given breakthroughs in utilizing biomarkers to improve drug approval probability
- Address emergency testing needs given new COVID-19 priorities
- Globalize trial support given increasing demand
As an additional response to these unprecedented circumstances,
“The COVID-19 pandemic has prompted
In summary,
Employee-first Approach to Operations
Employees and their families are at the heart of our operations, and their wellbeing remains our top priority. Two weeks ago, we asked office-based employees whose duties allow them to work remotely to work from home. We have taken steps to provide enhanced communications and tools to make our remote operations seamless with our internal operations. We have implemented best-in-class protocols to minimize the risk of exposure and virus spread for essential personnel in our
Redirecting Resources to
Emerging data suggests that in some coronavirus infected people, especially the elderly and sick, a dysfunctional immune system that fails to keep the response in check is associated with disease progression. Recent data also indicates that elevated cytokine levels, sometimes called cytokine storms, can be a predictor of clinical morbidity in COVID-19 patients.
Our Simoa technology provides researchers with the capability to conduct highly sensitive and accurate multiplexed tests for cytokines and chemokines in serum and plasma. We have published a letter with the four categories in which our technology is currently being deployed at a rapid pace by research organizations around the world. Those four categories include:
- Studying the Key Role of Inflammation in Disease Progression and Severity
- Characterizing Links between Viral Infection and Neurological Manifestations
- Measuring the Earliest Biomarkers of Myocardial Injury and Risk of Acute and Chronic Cardiac Disease
- Developing New Ultra-Sensitive Assays for Viral Detection and Host Response
Our approach to the direct detection of SARS-CoV-2 virus particles builds on our historical work with HIV, where our p24 assays kits were proven capable of detecting active HIV infection as much as 10 days earlier than other established methods. This work provided an essential foundation for advancing a rapid, low-cost antigen assay to see the disease at its most infectious, pre-symptomatic phase. We believe a similar strategy can be employed to develop an ultra-sensitive COVID-19 test using our technology. As such, we are devoting resources to harnessing our in-depth knowledge of infectious disease pathology, unique and highly sensitive assay capabilities, and CLIA-Licensed
“We strongly believe our technology and the
Overall Business Outlook and Uncertainty
We remain committed to supporting the needs of our employees, customers and society in the face of this unprecedented crisis. With the fast-moving nature of the current environment, we cannot rule out the future impact of the COVID-19 pandemic on our business. In anticipation of this situation, however, we took proactive steps before the crisis became broad-based to protect our employees and re-align our organization to support the needs of our customers and COVID-19 researchers quickly. Our strong balance sheet provides financial flexibility to maintain our essential operations and financial strength to support our strategic pursuits. As this situation unfolds over the next several months, we will continue to proactively manage and navigate the crisis to protect our employees and their families, while we optimize business operations for customers, collaborators and investors. Despite the present near-term challenges, we remain positive and committed to the unprecedented opportunity before the research markets and, ultimately, across clinical diagnostic markets.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005265/en/
Media Contacts:
quanterix@pancomm.com
Investor Relations Contact:
(774) 278-0496
shrusovsky@quanterix.com
Source: